Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928140 | 0.86 | PTGER4 (0.50) | TDP1ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL29562418 | 0.84 | SLC16A3 (0.58) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL928055 | 0.84 | SLC16A3 (0.58) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| Water SCHEMBL9265852 | 0.83 | SLC16A3 (0.56) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL929442 | 0.82 | PTGER4 (0.51) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL927912 | 0.82 | SLC16A3 (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL27941757 | 0.80 | CNR1 (0.58) | TDP1MCL1CCR2ALDH1A1LMNA | |
| SCHEMBL927918 | 0.80 | CNR1 (0.64) | ALDH1A1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14584216 | 0.79 | CYP2C9 (0.65) | TDP1MCL1CCR2ALDH1A1LMNA | |
| SCHEMBL927411 | 0.78 | SLC16A3 (0.80) | CCR2SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS INC (CA) | 2019-11-07 | — | — | US | disclosed |
| EP-2262778-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | ACRAF (IT) | 2019-08-21 | — | — | EP | disclosed |
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2018-08-09 | — | — | US | disclosed |
| EP-3310353-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | Translatum Medicus, Inc. (CA) | 2018-04-25 | — | — | EP | disclosed |
| EP-3181551-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-06-21 | — | — | EP | disclosed |
| EP-2254869-B1 | NEUE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 UND P40 | ACRAF (IT) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016203313-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | TRANSLATUM MEDICUS, INC. (CA) | 2016-12-22 | — | — | WO | disclosed |
| EP-2254870-B1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | ACRAF (IT) | 2016-02-24 | — | — | EP | disclosed |
| US-9255073-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-02-09 | — | — | US | disclosed |
| US-8835481-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN.ANG.FRANC. A.C.R.A.F. S.p.A. (IT) | 2011-04-07 | — | — | US | disclosed |
| US-7919518-B2 | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2011-04-05 | — | — | US | disclosed |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
| EP-2262778-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CXCR1 AND P40 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-22 | — | — | EP | disclosed |
| US-20100311744-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A. (IT) | 2010-12-09 | — | — | US | disclosed |
| EP-2254869-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| EP-2254870-A2 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. (IT) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009109618-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109613-A2 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109616-A2 | NOVEL 1-BENZIL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221339-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | TDP1 2450/4885MCL1 4228/4885CCR2 3404/4885 |
| US-20190336482-A1 | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING OCULAR DISORDERS | UACA, PDE6C, EYA3 | TDP1 2450/4885MCL1 4228/4885CCR2 3404/4885 |
| US-20110082141-A1 | 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | TDP1 1536/4885MCL1 124/4885CCR2 2/4885 |
| US-20110003874-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | TDP1 1781/4885MCL1 128/4885CCR2 2/4885 |
| US-20100311744-A1 | NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40 | CX3CR1, CCR2, CCR5 | TDP1 1781/4885MCL1 128/4885CCR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.